Key Points:
Business Performance
- Neurocrine generated Q3 2026, Neurocrine generated revenue of $1.123 billion, representing growth of 41% compared to the previous year. [assets.neu...ocrine.com]
- The three most important products:
- INGREZZA: $801 million in revenue (+17% YoY)
- CRENESSITY: $211 million in revenue
- VYKAT XR: $107 million in revenue (first full quarter following the Soleno acquisition) [assets.neu...ocrine.com]
Profitability
- Non-GAAP net income: $347 million (+56% YoY). [assets.neu...ocrine.com]
- Diluted non-GAAP EPS: $3.29 compared to $2.17 in the prior year (+52%). [assets.neu...ocrine.com]
Outlook
- The forecast for INGREZZA for 2026 has been raised:
- Previously: $2.825 to $2.875 billion
- New: $2.9 to $2.925 billion Revenue. [assets.neu...ocrine.com]
Financial Position
- As of September 30, 2026, the company had $790 million in cash and investments. [assets.neu...ocrine.com]
- The year-over-year decline is primarily attributable to the acquisition of Soleno Therapeutics . [assets.neu...ocrine.com]
Pipeline and Research
- Neurocrine highlights a strong pipeline in the following areas:
- neuropsychiatry
- Endocrinology
- Immunology. [assets.neu...ocrine.com]
- In 2026, several new Phase 1 and Phase 2 programs were launched, including those for:
- Alzheimer’s
- Schizophrenia
- Obesity
- Tardive dyskinesia. [assets.neu...ocrine.com]
- For 2027, 9 major study data releases are expected. [assets.neu...ocrine.com]
Key Message for Investors
Management presents Neurocrine as a company with:
From an investor’s perspective, the the increase in the INGREZZA forecast to up to $2.925 billion is the most important short-term positive highlight of this presentation. [assets.neu...ocrine.com]
- a rapidly growing core business (INGREZZA),
- a successful second revenue driver (CRENESSITY),
- additional growth through the Soleno acquisition (VYKAT XR),
- and a broad pipeline for the coming years. [assets.neu...ocrine.com]